Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Furio ColivicchiMichele Massimo GuliziaMarcello ArcaPier Luigi TemporelliLucio GonziniVanessa VenturelliNuccia MoriciCiro IndolfiDomenico GabrielliLeonardo De LucaPublished in: Cardiovascular therapeutics (2020)
Post-MI patients are undertreated with conventional lipid lowering therapies. A minority of post-MI patients would be eligible to PCSK9 inhibitors according to ESC/EAS guidelines and Italian regulatory agency criteria.